South Korea Steps Up Stem-Cell Work
By Soo Bin Park,
Nature News
| 05. 01. 2012
The South Korean health ministry announced last month that research into stem cells and regenerative medicine will receive a funding boost of 33 billion won (US$29 million) in 2012, four times that given in 2011. Overall, six different ministries will invest 100 billion won in stem-cell research this year.
Until last year, public investment in stem cells in South Korea was relatively low and targeted mainly at basic research. But the country's Ministry of Health and Welfare is now expanding its support for clinical research on stem cells, with the money being used to link basic research to intermediate or clinical studies. The aim is to commercialize the research at an early stage.
"From the current research atmosphere and infrastructure, the government has judged that stem-cell studies are now maturing," says Hyung Min Chung, president of Seoul-based biotechnology firm Cha Bio and Diostech and an adviser on the budget plan. He adds that his company is particularly pleased that government investment decisions on developing stem-cell therapies will be made more quickly.
Target market
The government money will be allocated to...
Related Articles
By Judd Boaz and Elise Kinsella, ABC News | 03.17.2026
By Gabriele Pichlhofer and Tino Plümecke, Guest Contributors
| 03.25.2026
A German translation of this interview will be published in May 2026 in the German GID MAGAZIN, which focuses on the market for reproductive technologies. For more information, visit: Gen-ethisches Netzwerk
Egg donation is currently prohibited in Germany and Switzerland, but both countries have been debating its legalization for years. In Switzerland, a legal framework is currently being developed, with a first draft expected by the end of the year. Yet the debate rarely draws on scientific evidence. Instead...
By Charles Pulliam-Moore, The Verge | 03.21.2026
Like many people, director Valerie Veatch was intrigued when OpenAI first released its Sora text-to-video generative AI model to the public in 2024. Though she didn’t fully understand the technology, she was curious about what it could do, and she...
By Ritsuko Kawai, Wired | 03.14.2026
On March 6, Japan’s Ministry of Health, Labor and Welfare officially granted conditional and time-limited marketing authorization to two regenerative medical products derived from reprogrammed iPS cells, marking exactly 20 years since the creation of mouse iPS cells.These will...